Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beximco PharmaceuticalsBXMPY 93 3-1 Month Momentum % is N/A% as of Aug. 18, 2026. GuruFocus rates BXMPY with a GF Score™ of 93/100. The stock has 6 warning signs investors should review. Among 1,027 Drug Manufacturers companies, Beximco Pharmaceuticals ranks better than 91.24% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-18), Beximco Pharmaceuticals's 3-1 Month Momentum % is N/A%.
The industry rank for Beximco Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
BXMPY's 3-1 Month Momentum % is not ranked *
in the Drug Manufacturers industry.
Industry Median: -5.65 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Beximco Pharmaceuticals 3-1 Month Momentum % Related Terms
BXMPY vs ZTS, UTHR, VTRS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beximco Pharmaceuticals (BXMPY) has a 3-1 Month Momentum % of N/A% as of Aug. 18, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Beximco Pharmaceuticals and its competitors. According to the industry distribution chart, Beximco Pharmaceuticals ranks #90 out of 1027 companies in the Drug Manufacturers industry, placing it in the top 8.8%.
Is Beximco Pharmaceuticals' 3-1 Month Momentum % too high?
Beximco Pharmaceuticals' current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Beximco Pharmaceuticals ranks #90 out of 1027 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Beximco Pharmaceuticals has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' 3-1 Month Momentum % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #90 out of 1027 companies for 3-1 Month Momentum %. This places Beximco Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Beximco Pharmaceuticals' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current 3-1 Month Momentum % is N/A% as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXMPY has been successfully added to your 
